Related Experiment Videos
COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma
D B Boyd1, M Coleman, S W Papish
1Division of Hematology-Oncology, New York Hospital, New York.
Summary
The COPBLAM III regimen shows high efficacy in treating diffuse large-cell lymphoma, achieving an 84% complete response rate. Younger patients (≤60) experienced superior outcomes compared to elderly patients, who faced increased toxicity.
Area of Science:
- Oncology
- Clinical Medicine
- Pharmacology
Background:
- Diffuse large-cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Effective polychemotherapy regimens are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of the COPBLAM III regimen in patients with DLCL.
- To compare treatment outcomes between younger and elderly patient cohorts.
Main Methods:
- A cohort of 51 DLCL patients received COPBLAM III (cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine).
- Patient responses, relapse rates, survival data, and toxicity were assessed.
- Outcomes were stratified by age (≤60 years vs. >60 years).
Main Results:
- An overall complete response (CR) rate of 84% was achieved, with 92% sustained at a median follow-up of 40 months.
- Patients ≤60 years had a 96% CR rate with no relapses, while patients >60 years had a 73% CR rate.
- Pulmonary toxicity occurred in 39% of patients, leading to two deaths; elderly patients tolerated therapy less well.
Conclusions:
- COPBLAM III is a highly effective polychemotherapy regimen for DLCL.
- Age significantly impacts treatment tolerance and outcomes, with elderly patients experiencing higher toxicity and lower response rates.
- Long-term durable responses suggest COPBLAM III's potential for durable survival in DLCL.